HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

ONO-8430506

an autotaxin inhibitor; structure in first source

Networked: 5 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Pyridines: 88
    - Carbolines: 283
      - ONO-8430506: 5
- Fused-Ring Heterocyclic Compounds
  - 2-Ring Heterocyclic Compounds
    - Indoles: 200
      - Indole Alkaloids: 200
        Carbolines: 283
        ONO-8430506: 5
  - 3-Ring Heterocyclic Compounds
    - Carbolines: 283
      - ONO-8430506: 5

Experts

1.	Benesch, Matthew G K: 4 articles (09/2015 - 06/2014)
2.	Brindley, David N: 4 articles (09/2015 - 06/2014)
3.	Dewald, Jay: 4 articles (09/2015 - 06/2014)
4.	McMullen, Todd P W: 4 articles (09/2015 - 06/2014)
5.	Tang, Xiaoyun: 4 articles (09/2015 - 06/2014)
6.	Maeda, Tatsuo: 2 articles (06/2020 - 06/2014)
7.	Ohhata, Akira: 2 articles (06/2020 - 06/2014)
8.	Curtis, Jonathan M: 2 articles (08/2015 - 06/2014)
9.	Zhao, Yuan Y: 2 articles (08/2015 - 06/2014)
10.	Hiramatsu, Atsushi: 1 article (06/2020)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 06/01/2014 - "The effects of ONO-8430506 on tumor growth were determined in a syngeneic orthotopic mouse model of breast cancer following injection of 20,000 BALB/c mouse 4T1 or 4T1-12B cancer cells. " 06/11/2020 - "Further optimization to improve the pharmacokinetic profile and enhance the ATX inhibitory activity in human plasma resulted in the identification of ONO-8430506 (20), which enhanced the antitumor effect of paclitaxel in a breast cancer model." 03/01/2015 - "Blocking LPA production with 10 mg/kg per d ONO-8430506 (competitive autotaxin inhibitor, IC90 = 100 nM) decreased expression of Nrf2, multidrug-resistant transporters, and antioxidant genes in breast tumors by ≤90%. " 09/01/2015 - "ONO-8430506 also decreased plasma TNF-α and G-CSF cytokine levels by >70% and leukocyte infiltration in breast tumors and adjacent adipose tissue by >50%. "
2.	Neoplasms (Cancer) 09/01/2015 - "Blocking ATX activity in mice bearing 4T1 tumors with 10 mg/kg/d ONO-8430506 (a competitive ATX inhibitor, IC90 = 100 nM; Ono Pharma Co., Ltd., Osaka, Japan) broke this vicious inflammatory cycle by decreasing 20 inflammatory mediators by 1.5-8-fold in cancer-inflamed adipose tissue. " 06/01/2014 - "The effects of ONO-8430506 on tumor growth were determined in a syngeneic orthotopic mouse model of breast cancer following injection of 20,000 BALB/c mouse 4T1 or 4T1-12B cancer cells. " 03/01/2015 - "Combining 4 mg/kg doxorubicin every third day with ONO-8430506 synergistically decreased tumor growth and metastasis to lungs and liver by >70%, whereas doxorubicin alone had no significant effect. "
3.	Neoplasm Metastasis (Metastasis) 03/01/2015 - "Combining 4 mg/kg doxorubicin every third day with ONO-8430506 synergistically decreased tumor growth and metastasis to lungs and liver by >70%, whereas doxorubicin alone had no significant effect. "
4.	Papillary Thyroid Cancer 08/01/2015 - "We confirmed that this autotaxin/inflammatory cycle occurs in two SCID mouse models of papillary thyroid cancer by blocking LPA signalling using the autotaxin inhibitor ONO-8430506. "

Related Drugs and Biologics

1.	Paclitaxel (Taxol)
2.	Cytokines
3.	Granulocyte Colony-Stimulating Factor (G-CSF)
4.	Doxorubicin (Adriamycin)
5.	Antioxidants